Novavax, Inc. (NVAX) News

Novavax, Inc. (NVAX): $14.40

0.65 (-4.32%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

C

Add NVAX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#50 of 351

in industry

Filter NVAX News Items

NVAX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVAX News Highlights

  • NVAX's 30 day story count now stands at 8.
  • Over the past 15 days, the trend for NVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about NVAX are DRUG, NVX and EYE.

Latest NVAX News From Around the Web

Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

Smart Shorts: 7 Meme Stocks to Bet Against in 2024

These seven meme stocks have surged as speculators declare "the coast is clear," but a big reversal for each of them may be forthcoming.

Thomas Niel on InvestorPlace | December 28, 2023

3 Heavily Shorted Stocks That Still Won’t See a Squeeze

These are the heavily shorted stocks to avoid as they are likely to continue trending lower on the back of very weak fundamentals.

Faisal Humayun on InvestorPlace | December 25, 2023

Is Novavax Stock A Buy On Its Covid Vaccine Launch Spree?

Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now?

Yahoo | December 20, 2023

Owning 48% shares,institutional owners seem interested in Novavax, Inc. (NASDAQ:NVAX),

Key Insights Significantly high institutional ownership implies Novavax's stock price is sensitive to their trading...

Yahoo | December 19, 2023

3 Meme Stocks That Could Fade Away in 2024

These are the meme stocks to avoid or sell as they have extremely weak fundamentals and are unlikely to recover from a financial perspective.

Faisal Humayun on InvestorPlace | December 18, 2023

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Yahoo | December 18, 2023

UPDATE 2-US CDC says there's urgent need to increase respiratory vaccine coverage

The U.S. Centers for Disease Control and Prevention (CDC) on Thursday issued an alert urging healthcare providers to increase immunization coverage for influenza, COVID-19 and respiratory syncytial virus (RSV). The health regulator said that low vaccination rates, coupled with ongoing increases in respiratory disease activity, could lead to more severe disease and increased healthcare capacity strain in the coming weeks. Healthcare providers should recommend antiviral medications for influenza and COVID-19 for all eligible patients, especially older adults and people with certain underlying medical condition, the CDC said.

Yahoo | December 14, 2023

Canadians Can Help Protect Loved Ones as We Head into the Holiday Season

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced the launch of Choose to Protect™, a campaign to educate the public about the importance of COVID-19 vaccination and COVID-19 vaccines. Since 2020, COVID-19 has become one of the leading causes of death in Canada.i,ii The campaign will feature resources in both English and French.

Yahoo | December 13, 2023

UPDATE 1-Health Canada authorizes Novavax's updated COVID shot for Omicron

Novavax said on Tuesday that Health Canada had authorized its updated COVID-19 vaccine, targeting the Omicron subvariant XBB.1.5, in individuals aged 12 years and older. Last month, WHO granted emergency-use authorization to the vaccine, which targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this year. The U.S. Food and Drug Administration and the European Commission authorized the use of the updated vaccine in October.

Yahoo | December 5, 2023

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older. The Public Health Agency of Canada's National Advisory Committee on Immunization recommended XBB COVID-19 vaccines that target more recent, imm

Yahoo | December 5, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!